PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Thymoglobulin

Drugs in development · updated 30 October 2026

Thymoglobulin: clinical trials and development status

Other names and codes: Rabbit Anti thymocyte globulin, Rabbit ATG

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Thymoglobulin is in 19 active clinical trials (recruiting or ongoing, phases I–III) for 33 diseases. The most advanced phase is III.

19Active trials
IIIMost advanced phase
33Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Thymoglobulin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 33 diseases.

DiseaseMost advanced phaseActive trialsReference trial
LeukemiaIII1NCT04547049
Acute myeloid leukemiaII4NCT04888741
Hematologic neoplasmII3NCT05735717
Myelodysplastic SyndromesII3NCT04888741
Sickle-cell diseaseII3NCT06872333
Aplastic anemiaII2NCT02828592
HemoglobinopathiesII2NCT06872333
Hodgkin lymphomaII2NCT04888741
Multiple myelomaII2NCT04888741
Non-Hodgkin lymphomaII2NCT04888741
Precursor lymphoblastic lymphoma/leukemiaII2NCT04888741
ThalassemiaII2NCT05736419
Acquired amegakaryocytic thrombocytopeniaII1NCT06412497
B-cell leukemiaII1NCT03852407
Beta thalassemiaII1NCT05736419
Chromosome 7, monosomyII1NCT05735717
Chromosome AberrationsII1NCT05735717
Chronic myelomonocytic leukemiaII1NCT04888741
ColitisII1NCT03219359
Crohn's diseaseII1NCT03219359
CytopeniaII1NCT02143830
Fanconi anemiaII1NCT02143830
GastroenteritisII1NCT03219359
Graft-versus-host diseaseII1NCT03852407
Inflammatory bowel diseasesII1NCT03219359
Juvenile myelomonocytic leukemiaII1NCT05735717
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII1NCT04888741
MyelofibrosisII1NCT04888741
Myeloproliferative disordersII1NCT03852407
Neurofibromatosis 1II1NCT05735717

Everything on Thymoglobulin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch